난청 질환 치료 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 질환별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Hearing Loss Disease Treatment Market Size, Share & Trends Analysis Report By Product (Devices, Drugs), By Disease (Conductive, Sensorineural), By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,269,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,659,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,438,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

난청 질환 치료 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 난청 질환 치료 시장 규모는 2025-2030년 연평균 복합 성장률(CAGR) 7.29%를 기록할 전망이며, 2030년에는 175억 1,000만 달러에 달할 것으로 예측됩니다.

이 성장의 배경에는 세계의 질병 부담 증가, 사람들의 의식을 넓히기 위해 정부나 민간 단체가 실시하고 있는 대처, 세계 노인 인구 증가가 있습니다. 또한 임상 파이프라인 의약품 증가나 청각 디바이스의 진보는 업계의 성장에 유리한 기회를 제공합니다. 세계에서는 난청 환자가 증가하고 있으며, 이것이 업계의 성장을 촉진하는 주된 요인이 되고 있습니다.

예를 들어 WHO의 보고에 따르면 2021년에는 세계 인구의 5% 이상, 약 4억 3,000만 명이 청력 장애를 관리하기 위한 재활을 필요로 했습니다. 게다가 2050년에는 전 세계적으로 약 25억 명이 청력 장애의 영향을 받는 것으로 추정되고 있습니다. 보고서에 따르면 중저소득 국가가 장애로 고통받는 사람들의 80%를 차지하고 있습니다. 고령화가 더욱 유병률의 상승으로 이어지고 있습니다. 전 세계적으로는 60세의 약 25%가 난청으로 이환되고 있습니다. 따라서 질병의 증가는 치료 수요를 증가시켜 이 분야를 견인하고 있습니다. 이 분야에는 견고한 임상시험 파이프라인이 존재하며 향후 몇 년간 더 나은 치료 옵션이 제공될 것으로 기대됩니다.

이것은 임상시험의 다양한 단계에서 45가지 이상의 치료법의 존재로 예상됩니다. 예를 들어 Sound Pharmaceuticals사의 Ebselen과 Sensorion사의 SENS-401은 각각 메니에르병과 감음성 난청 치료를 적응으로 하는 3상 임상시험 중입니다. 마찬가지로 2022년 6월에는, 파이프라인 세라퓨틱스사의 제2상 시험약 PIPE-505가 감음성 난청을 대상으로 평가되고 있습니다. 따라서 향후 몇 년간 새로운 치료 옵션의 출시는 업계에 유리한 기회를 제공할 것으로 예상됩니다. 청각 제품에 있어서 AI 관련 혁신 등의 기술 진보의 고조가 업계를 지지하고 있습니다.

스마트폰에서의 조작이나 충전식 및 방수 디바이스 등, 첨단 기능을 갖춘 제품의 발매는 고객 경험을 향상시키고 있습니다. 예를 들면, GN 히어링은 2022년 6월, Android나 iOS로부터의 무선 스트리밍에 대응한 충전식 보청기 'Custom made by Resound'를 발매했습니다. 주요 기업은 신출시, 제휴, 계약, 재무 투자 등의 전략적 이니셔티브를 실시하고 있으며, 이것이 업계를 더욱 견인하고 있습니다. 예를 들어, 2022년 4월, 오티젠은 베링거인겔하임과 감음성 질환으로 고통받는 사람들을 위한 선진적인 치료법을 개발하기 위한 공동 연구 및 라이선스 계약을 체결했습니다. 마찬가지로 2022년 9월, 페넥 제약은 페드마크토가 화학요법을 받는 소아 환자의 난청을 막는다는 FDA 승인을 발표했습니다.

난청 질환 치료 시장 보고서 하이라이트 :

• 2024년에는 디바이스 분야가 업계를 지배하여 전체 수익의 91.02% 이상의 최대 점유율을 차지했습니다. 이는 디바이스의 기술적 진보, 디바이스의 이점 증대와 맞물려 높은 보급률에 기인합니다.
• 약물 부문은 새로운 치료 제품의 출시로 예측 기간 동안 가장 빠른 CAGR을 나타낼 것으로 추정됩니다. 약제는 몇 가지 유형의 청각 장애에 이용할 수 있습니다.
• 감음성 난청 분야는 2024년 업계를 지배해 총 수입의 65.24% 이상의 최대 점유율을 차지하며 예측 기간에서 가장 급성장하는 분야로 예측됩니다.
• 북미의 난청 질환 치료 산업은 2024년 세계 점유율의 31.32%를 차지하고 주도적 지위를 차지했습니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 난청 질환 치료 시장의 변수, 동향 및 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 사회적 스티그마의 존재
• 저중소득국(LMIC)의 불충분한 상환제도
• 비즈니스 환경 분석
  • 업계 분석-Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석

제4장 난청 질환 치료 시장 : 제품별 비즈니스 분석

• 제품별 시장 점유율(2024년, 2030년)
• 제품별 부문 대시보드
• 시장 규모, 예측 및 동향 분석 : 제품별(2018-2030년)
• 디바이스
• 약물

제5장 난청 질환 치료 시장 : 질환별 비즈니스 분석

• 질환별 시장 점유율(2024년, 2030년)
• 질환별 부문 대시보드
• 시장 규모, 예측 및 동향 분석 : 질환별(2018-2030년)
• 전음성 난청
• 감음 난청
• 혼합형(전음성과 감음성)

제6장 난청 질환 치료 시장 : 최종 용도별 비즈니스 분석

• 최종 용도별 시장 점유율(2024년, 2030년)
• 최종 용도별 부문 대시보드
• 시장 규모, 예측 및 동향 분석 : 최종 용도별(2018-2030년)
• 병원
• 이비과 클리닉
• 외래 진료소

제7장 난청 질환 치료 시장 : 지역별 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 시장 규모와 예측 및 동향 분석(2018-2030년)
• 북미
  • 국가별(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일 및 목록
  • Novartis AG
  • Spiral Therapeutics(Otonomy, Inc.)
  • Acousia Therapeutics Gmbh
  • Sensorion
  • Audina Hearing Instruments, Inc.
  • Ws Audiology A/S
  • audifon Gmbh & Co. Kg
  • MED-EL Medical Electronics
  • Demant A/S
  • Sonova

AJY

영문 목차

영문목차

Hearing Loss Disease Treatment Market Growth & Trends:

The global hearing loss disease treatment market size is expected to reach USD 17.51 billion by 2030, registering a CAGR of 7.29% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the growing geriatric population in the world. Furthermore, the increasing number of clinical pipeline drugs and advancements with auditory devices offer lucrative opportunities for industry growth. The world is witnessing an increasing prevalence of hearing loss cases, which is the key factor driving the industry's growth.

For instance, according to the WHO reports, in 2021, over 5% of the world's population, or around 430 million people, require rehabilitation to manage their listening disability. Moreover, by 2050, nearly 2.5 billion people are estimated to be impacted by listening impairment across the globe. As per the report, low- and middle-income countries account for 80% of people suffering from a disability. Aging has further led to an increase in the prevalence of the disease. Globally, approximately 25% of people aged 60 years are affected by hearing loss. Therefore, the rising disease cases increase the demand for treatment and drive the space. The space has the presence of a robust clinical trial pipeline, which is expected to offer better treatment options in the coming years.

This can be anticipated due to the presence of more than 45 therapies at different phases of clinical investigation. For instance, Sound Pharmaceuticals' Ebselen and Sensorion's SENS-401 are under phase 3 clinical studies indicated for the treatment of Meniere's Disease and sensorineural hearing loss, respectively. Similarly, in June 2022, Pipeline Therapeutics' phase 2 drug, PIPE-505 is being evaluated for sensorineural hearing loss. Therefore, the launch of new treatment options in the coming years is expected to offer a lucrative opportunity for the industry. Rising technological advancements, such as AI-associated innovations, in auditory products, are boosting the industry.

The launch of products with advanced features like operating through smartphones and rechargeable & waterproof devices is enhancing customer experience. For instance, in June 2022, GN Hearing launched Custom made by Resound, a chargeable hearing aid that supports wireless streaming from Android and iOS. Key players are implementing strategic initiatives, such as new launches, collaborations, agreements, and financial investments, which are further driving the industry. For instance, in April 2022, Autigen entered into a collaboration and licensing agreement with Boehringer Ingelheim to develop advanced therapies for people suffering from sensorineural conditions. Similarly, in September 2022, Fennec Pharmaceuticals announced the FDA approval for Pedmarkto prevents hearing loss in pediatric patients going through chemotherapy.

Hearing Loss Disease Treatment Market Report Highlights:

• The devices segment dominated the industry in 2024 and accounted for the maximum share of more than 91.02% of the overall revenue. This can be attributed to technological advancements in devices, high prevalence coupled with the rising benefits of devices.
• The drugs segment is estimated to register the fastest CAGR over the forecast period due to the launch of new therapeutic products. Drugs are available for several types of hearing problems.
• The sensorineural hearing loss segment dominated the industry in 2024 and accounted for the maximum share of more than 65.24% of the total revenue and is estimated to be the fastest growing segment over the forecast period.
• North America hearing loss disease treatment industry held the leading position in 2024, accounting for 31.32% of the global share

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease
  • 1.2.3. End User
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hearing Loss Disease Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in the number of patients with hearing loss
    • 3.2.1.2. Strong research and development pipeline
    • 3.2.1.3. Technological advancements in hearing aids
  • 3.2.2. Market Restraint Analysis
• 3.3. 3.3.1 Presence of social stigmas
• 3.4. 3.3.2 Poor reimbursement facilities in low- and middle-income countries (LMICs)
• 3.5. Business Environment Analysis
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier Power
    • 3.5.1.2. Buyer Power
    • 3.5.1.3. Substitution Threat
    • 3.5.1.4. Threat of New Entrants
    • 3.5.1.5. Competitive Rivalry
  • 3.5.2. PESTLE Analysis
  • 3.5.3. Pipeline Analysis

Chapter 4. Hearing Loss Disease Treatment Market: Products Business Analysis

• 4.1. Products Market Share, 2024 & 2030
• 4.2. Products Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Products, 2018 to 2030 (USD Million)
• 4.4. Devices
  • 4.4.1. Devices Market, 2018 - 2030 (USD Million)
• 4.5. Drugs
  • 4.5.1. Drugs Market, 2018 - 2030 (USD Million)
  • 4.5.2. Systemic steroids
    • 4.5.2.1. Systemic steroids Market, 2018 - 2030 (USD Million)
  • 4.5.3. Antiviral medication
    • 4.5.3.1. Antiviral medication Market, 2018 - 2030 (USD Million)
  • 4.5.4. Vasodilators
    • 4.5.4.1. Vasodilators Market, 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Hearing Loss Disease Treatment Market: Disease Business Analysis

• 5.1. Disease Market Share, 2024 & 2030
• 5.2. Disease Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 5.4. Conductive Hearing Loss
  • 5.4.1. Conductive Hearing Loss Market, 2018 - 2030 (USD Million)
• 5.5. Sensorineural Hearing Loss
  • 5.5.1. Sensorineural Hearing Loss Market, 2018 - 2030 (USD Million)
• 5.6. Mixed (Conductive and Sensorineural)
  • 5.6.1. Mixed (Conductive and Sensorineural) Market, 2018 - 2030 (USD Million)

Chapter 6. Hearing Loss Disease Treatment Market: End User Business Analysis

• 6.1. End User Market Share, 2024 & 2030
• 6.2. End User Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End User, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
• 6.5. Otology clinics
  • 6.5.1. Otology clinics Market, 2018 - 2030 (USD Million)
• 6.6. Ambulatory clinics
  • 6.6.1. Ambulatory clinics Market, 2018 - 2030 (USD Million)

Chapter 7. Hearing Loss Disease Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Hearing Loss Disease Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Hearing Loss Disease Treatment Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Hearing Loss Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Novartis AG
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Spiral Therapeutics (Otonomy, Inc.)
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Acousia Therapeutics Gmbh
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Sensorion
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Audina Hearing Instruments, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Ws Audiology A/S
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. audifon Gmbh & Co. Kg
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. MED-EL Medical Electronics
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Demant A/S
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Sonova
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료